DK2123630T3 - 2-Amino-bicyclo[3.1.0]hexan-2,6-dicarboxylsyreesterderivat - Google Patents

2-Amino-bicyclo[3.1.0]hexan-2,6-dicarboxylsyreesterderivat

Info

Publication number
DK2123630T3
DK2123630T3 DK09166100.9T DK09166100T DK2123630T3 DK 2123630 T3 DK2123630 T3 DK 2123630T3 DK 09166100 T DK09166100 T DK 09166100T DK 2123630 T3 DK2123630 T3 DK 2123630T3
Authority
DK
Denmark
Prior art keywords
hydrogen atom
bicyclo
hexane
amino
alkyl group
Prior art date
Application number
DK09166100.9T
Other languages
English (en)
Inventor
Akito Yasuhara
Kazunari Sakagami
Hiroshi Ohta
Atsuro Nakazato
Original Assignee
Braincells Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Braincells Inc filed Critical Braincells Inc
Application granted granted Critical
Publication of DK2123630T3 publication Critical patent/DK2123630T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C221/00—Preparation of compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Detergent Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
DK09166100.9T 2003-06-26 2004-06-25 2-Amino-bicyclo[3.1.0]hexan-2,6-dicarboxylsyreesterderivat DK2123630T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2003181930 2003-06-26
JP2003373511 2003-10-31
JP2004128663 2004-04-23
EP04746867A EP1637517B1 (en) 2003-06-26 2004-06-25 2-aminobicyclo 3.1.0 hexane-2,6-dicarboxylic ester derivative

Publications (1)

Publication Number Publication Date
DK2123630T3 true DK2123630T3 (da) 2012-10-22

Family

ID=33556154

Family Applications (2)

Application Number Title Priority Date Filing Date
DK04746867.3T DK1637517T3 (da) 2003-06-26 2004-06-25 2-Amino-bicyclo[3.1.0]hexan-2,6-dicarboxylsyreesterderivat
DK09166100.9T DK2123630T3 (da) 2003-06-26 2004-06-25 2-Amino-bicyclo[3.1.0]hexan-2,6-dicarboxylsyreesterderivat

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK04746867.3T DK1637517T3 (da) 2003-06-26 2004-06-25 2-Amino-bicyclo[3.1.0]hexan-2,6-dicarboxylsyreesterderivat

Country Status (21)

Country Link
US (5) US7960579B2 (da)
EP (3) EP2123630B1 (da)
JP (1) JP4792971B2 (da)
KR (1) KR101071507B1 (da)
AT (1) ATE487690T1 (da)
AU (2) AU2004252017B2 (da)
BR (1) BRPI0411823A (da)
CA (1) CA2530706C (da)
CY (1) CY1110997T1 (da)
DE (1) DE602004030007D1 (da)
DK (2) DK1637517T3 (da)
ES (1) ES2394175T3 (da)
HK (1) HK1095318A1 (da)
HR (1) HRP20100619T1 (da)
MX (1) MXPA05013740A (da)
NO (1) NO335004B1 (da)
NZ (2) NZ544131A (da)
PL (1) PL1637517T3 (da)
PT (1) PT1637517E (da)
SI (1) SI1637517T1 (da)
WO (1) WO2005000791A1 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000791A1 (ja) * 2003-06-26 2005-01-06 Taisho Pharmaceutical Co., Ltd. ２－アミノ－ビシクロ[３．１．０]ヘキサン－２，６－ジカルボン酸エステル誘導体
TW201129700A (en) 2009-11-18 2011-09-01 Taisho Pharmaceutical Co Ltd Method for producing optically active bicyclo [310] hexane derivative using oxygen
WO2011061935A1 (ja) * 2009-11-19 2011-05-26 大正製薬株式会社 ３－アルコキシ－２－アミノ－６－フルオロビシクロ［３．１．０］ヘキサン－２，６－ジカルボン酸誘導体及びその中間体の製造方法
MX2013005623A (es) * 2010-11-18 2013-07-05 Lilly Co Eli Compuestos de 3-benciloxi-biciclico [3.1.0] hexano 4-sustituidos como antagonistas de mglur 2/3.
TWI520935B (zh) 2010-11-18 2016-02-11 美國禮來大藥廠 作為ｍＧｌｕＲ２／３拮抗劑之４－經取代－３－苯基磺醯基甲基－雙環［３.１.０］己烷化合物
WO2013062680A1 (en) * 2011-10-25 2013-05-02 Braincells, Inc. Novel compounds and compositions thereof for treating nervous system disorders
AR089718A1 (es) 2012-02-01 2014-09-10 Lilly Co Eli AGONISTAS DE mGlu2/3
JP5983713B2 (ja) * 2013-11-29 2016-09-06 大正製薬株式会社 含フッ素アミノ酸のプロドラッグを含有する医薬
FR3026843B1 (fr) * 2014-10-03 2016-11-18 Univ Pierre Et Marie Curie (Paris 6) Procede de caracterisation du mecanisme de fissuration d'un materiau a partir de sa surface de rupture
HUE056046T2 (hu) 2016-04-18 2022-01-28 Taisho Pharmaceutical Co Ltd Aminosav-származék prodrogja
US11173145B2 (en) 2017-01-17 2021-11-16 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
KR101877672B1 (ko) 2017-04-03 2018-07-11 엘에스산전 주식회사 Ａｄ컨버터
US11046649B2 (en) 2018-07-17 2021-06-29 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
US11501618B1 (en) * 2018-10-19 2022-11-15 Amazon Technologies, Inc. Security device with user-configurable motion detection settings

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5661184A (en) 1994-08-12 1997-08-26 Eli Lilly And Company Psychiatric agents
GB9605429D0 (en) * 1995-11-16 1996-05-15 Lilly Co Eli Excitatory amino acid receptor antagonists
ZA983930B (en) 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
CN1247527C (zh) 1998-08-31 2006-03-29 大正制药株式会社 6－氟双环[3.1.0]己烷衍生物
JP4194715B2 (ja) 1998-08-31 2008-12-10 大正製薬株式会社 ６−フルオロビシクロ［３．１．０］ヘキサン誘導体
CH694053A5 (de) * 1998-09-03 2004-06-30 Hoffmann La Roche Verfahren zur Herstellung von 2-Amino-bicyclo[3.1.0]hexan-2,6-dicarbonsäure-Derivaten.
AU2001267854B2 (en) * 2000-06-28 2005-12-01 Taisho Pharmaceutical Co., Ltd. Novel dicarboxylic acid derivatives
EP1370519A1 (en) * 2001-02-22 2003-12-17 Eli Lilly And Company Synthetic excitatory amino acids
CA2471642C (en) * 2001-12-27 2011-05-24 Taisho Pharmaceutical Co., Ltd. 6-fluorobicyclo[3.1.0]hexane derivatives
WO2005000790A1 (ja) 2003-06-26 2005-01-06 Taisho Pharmaceutical Co., Ltd. ２－アミノビシクロ[３．１．０]ヘキサン－２，６－ジカルボン酸誘導体
JP2007063129A (ja) 2003-06-26 2007-03-15 Taisho Pharmaceut Co Ltd ２−アミノ−３−アルコキシビシクロ［３．１．０］ヘキサン誘導体
WO2005000791A1 (ja) * 2003-06-26 2005-01-06 Taisho Pharmaceutical Co., Ltd. ２－アミノ－ビシクロ[３．１．０]ヘキサン－２，６－ジカルボン酸エステル誘導体

Also Published As

Publication number Publication date
NZ544131A (en) 2009-11-27
NO20060428L (no) 2006-03-10
HRP20100619T1 (hr) 2011-01-31
PT1637517E (pt) 2011-01-31
NO335004B1 (no) 2014-08-25
US8258133B2 (en) 2012-09-04
HK1095318A1 (en) 2007-05-04
EP2287147A3 (en) 2011-05-18
EP2123630B1 (en) 2012-07-25
US8350060B2 (en) 2013-01-08
EP2287147A2 (en) 2011-02-23
US20090306408A1 (en) 2009-12-10
US20120028982A1 (en) 2012-02-02
PL1637517T3 (pl) 2011-04-29
EP2123630A1 (en) 2009-11-25
EP2287147B1 (en) 2013-05-15
AU2009217374B2 (en) 2011-03-03
AU2009217374A1 (en) 2009-10-08
KR101071507B1 (ko) 2011-10-10
KR20060024817A (ko) 2006-03-17
BRPI0411823A (pt) 2006-08-08
NZ580554A (en) 2011-01-28
US8039647B2 (en) 2011-10-18
EP1637517A1 (en) 2006-03-22
US20070021394A1 (en) 2007-01-25
US8076502B2 (en) 2011-12-13
CY1110997T1 (el) 2015-06-11
DK1637517T3 (da) 2011-01-31
JPWO2005000791A1 (ja) 2006-10-19
ATE487690T1 (de) 2010-11-15
CA2530706C (en) 2012-11-27
US20100298561A1 (en) 2010-11-25
DE602004030007D1 (en) 2010-12-23
EP1637517A4 (en) 2007-05-23
ES2394175T3 (es) 2013-01-23
AU2004252017B2 (en) 2009-10-08
SI1637517T1 (sl) 2011-01-31
JP4792971B2 (ja) 2011-10-12
MXPA05013740A (es) 2006-05-17
WO2005000791A1 (ja) 2005-01-06
AU2004252017A1 (en) 2005-01-06
US7960579B2 (en) 2011-06-14
EP1637517B1 (en) 2010-11-10
US20120004232A1 (en) 2012-01-05
CA2530706A1 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
HK1095318A1 (en) 2-aminobicyclo(3.1.0)hexane-2,6-dicarboxylic ester derivative
RS107504A (en) Benzofused heteroaryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compostions including the same, and methods for their use
MX2007004183A (es) Derivados de benzoimidazol utiles como agentes antiproliferacion.
MY139357A (en) Novel benzoimidazole derivatives useful as antiproliferative agents
GEP20022676B (en) 4-Phenyl-Pyridine Derivatives, Method for Their Production and Their Use for Treatment of Disorders Caused by Antagonist of NK-1 Receptors
CY1106645T1 (el) Παραγωγα 1,2,4 τριαμινοβενζολης χρησιμα για τη θεραπευτικη αντιμετωπιση διαταραχων του κεντρικου νευρικου συστηματος
ATE280170T1 (de) Cyclopenta(b)(1,4) diazepino(6,7,1-hi)indole als 5ht2c antagonisten
BRPI0413876A (pt) tienopiridin-fenilacetamidas e seus derivados úteis como agentes antiangiogênicos
EA200901162A1 (ru) Производные 1,4-дизамещённого 3-цианопиридона и их применение в качестве положительных модуляторов рецептора mglur2
IS8502A (is) Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
TW200726765A (en) Triazolopyridine cannabinoid receptor 1 antagonists
NO20055655D0 (no) Anvendelse av azetidinkarboksamidderivater i terapi
NO20052730L (no) Aminoalkosyindoler som 5-HT6-reseptorligander for behandling av CNS-lidelser
AP2002002664A0 (en) Cyclohexylamine derivative as subtype selective NMDA receptor antagonists.
ATE171374T1 (de) Verwendung von 1-(aminoalkyl)-3-quinoxalin-2-on derivaten zur herstellung von neuroprotektiven mitteln
MXPA05006271A (es) Metodo para el tratamiento de desordenes del movimiento usando derivados de acido barbiturico.
NZ533358A (en) 3,4-Dihydro-1H-isoquinolin-2-yl-derivatives for use as NK2 receptor antagonists
DE60135016D1 (de) Indolderivate und deren verwendung in medikamenten
ATE374366T1 (de) Aminophenoxyacetamid derivate und diese enthaltende pharmazeutische zusammensetzungen
HUP0302255A2 (hu) Szulfonamidszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
DK1082116T3 (da) Anvendelse af 4-piperidinmethanolderivater til behandling af neurologiske sygdomme
ATE553087T1 (de) Therapeutisches mittel gegen chronische obstruktive atemwegserkrankung und verfahren zur behandlung von chronisch obstruktiver atemwegserkrankung mit diesem mittel
NO20053612L (no) 1,2,4-triaminobenzenderivater nyttige for behandling av forstyrrelser i sentralnervesystemet
ECSP992984A (es) Derivados de isotiazol utiles como agentes anticancerosos